Recorded Webinar: Implementing N Latex FLC Kappa and Lambda Assays: From Validation to Daily Clinical Use.

Healthcare News | 2012-10-15


Implementation of the new Siemens free light chain (FLC) kappa and lambda assays offers improvements in precision of results, linearity, antigen-excess security, and lot-to-lot consistency versus traditional methods based on polyclonal antibodies.

Preparing your laboratory for the implementation of a new tumor-marker method often requires significant preparation, because such methods typically are not easily interchangeable.

Learn how the Royal Brisbane and Women’s Hospital in Brisbane, Australia, successfully validated the N Latex FLC kappa and lambda assays and is preparing for implementation into clinical routine. Join our complimentary webinar to learn about the hospital's experience with the N Latex FLC assays, as presented from both the laboratory's and the hematologist’s perspective.


Please note: This event is intended for healthcare professionals outside of the U.S. only.

The experts:

Jill Tate

Dept of Chemical Pathology, Pathology Queensland, Royal Brisbane and Women’s Hospital, Brisbane, Australia

Dr. Peter Mollee, MBBS

Dept of Hematology, Pathology Queensland, Princess Alexandra Hospital, Brisbane, Australia

Contact Center

International (English): +49 69 797 6602
You can call us Monday through Friday
8 am to 5 pm CET

The products mentioned herein are not commercially available in all countries. Due to regulatory reasons their future availability cannot be guaranteed. Please contact your local Siemens organization for further details.

Did this information help you?
Thank you for your response
We detected numbers and/or an '@' symbol in your comment. Are you trying to enter a phone number or email address so that we may contact you, please contact us via our email form instead.

Note: to get a direct personal response, please contact us via our email form.

Thank you